Sažetak
Background: To observe the short-term outcome of plasma adsorption（PA）therapy in amyotrophic lateral sclerosis (ALS).
Methods: 28 cases of ALS patients were recruited in this study, of which 20 were male and 8 were female with a mean age of 53.21 ±9.07 years and the average course of 33±23.35 months. The clinical manifestations were limb weakness (N=27), muscular atrophy (N=27), muscular tremor (N=5), dysphagia (N=12) and dysarthria (N=12). The clinical data of the patients recruited were graded by Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (ALSFRSR) : <10 (N=1), 11-20 (N=4), 21-30 (N=6), 31-40 (N=12), >40 (N=5). All patients received PA therapy once a week for three successive times after examining the conditions of blood coagulation and virus infection. PA therapy was supplemented with neurotrophic therapy meanwhile. All patients' clinical manifestations and scores of ALSFRSR before treatment and one week after treatment were evaluated and compared. The levels of serum superoxide dismutase (SOD), interleukin-10 (IL-10), serum creatine kinase (CK) and lactate dehydrogenase (LDH) before and after treatment were compared.
Results: After PA therapy, 14 patients have improved obviously in muscle strength, 4 patients in hypermyotonia partially, 3 patients in muscular tremor, 5 patients in dysarthria, 3 patients in salivation to some extent and 2 patients in swallowing function. The score of ALSFRSR after PA treatment (31.89±10.36) was remarkably higher than that before PA treatment (30.68±10.52) (P<0.01). The levels of SOD (155.10±21.87 u/ml) and IL-10 (138.06±185.88 pg/ml) after PA treatment were significantly higher than the levels before PA treatment (143.08.3±19.16 u/ml and 46.34±75.31 pg/ml, respectively) (P<0.05). The levels of CK (168.86±113.50 u/L) and LDH (152.07±32.65 u/L) after PA treatment were significantly lower than the levels before PA treatment (356.68±250.30 u/L and 181.36±33.74 u/L respectively) (P<0.01). At the end of follow-up period (November, 2016), five patients died of respiratory failure 16-21 months after PA treatment and two patents died from respiratory infections 15-20 months after PA treatment. 7 patients were still alive. The scores of ALSFRS-R of these patients were 13.00±13.37, obviously lower than those before PA treatment (36.71±8.56) (P<0.05) and 4 week after PA treatment (38.14±8.82) (P<0.05).
Conclusions: Plasma adsorption (PA) therapy has short-term therapeutic effects on ALS. The effects might be attributed to the anti-oxygen free radical effect by increasing SOD level and the anti-inflammation effect by increasing IL-10 level. As the efficacy of PA therapy was obtained in a small sample size and short follow-up period, the long-term observation of PA efficacy in treating ALS should be further investigated.
Ključne reči
Array
Array
Reference
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.